Literature DB >> 10912474

Helicobacter pylori gastritis in Africa.

E J Kuipers1, G A Meijer.   

Abstract

* Helicobacter pylori gastritis progresses to gland loss and intestinal metaplasia in a considerable proportion of colonized subjects. * The progression to atrophic gastritis is a slow process, occurring with an incidence of 1-2% per year. * The progression of chronic H. pylori gastritis is the same in Africa as in Europe and South America. * This supports the concept of H. pylori as a causative factor of pre-neoplastic conditions of the gastric mucosa; other factors must play a modulating role in the progression to cancer. H. pylori gastritis may progress to atrophic gastritis and lead to the development of intestinal metaplasia, dysplasia and eventually gastric cancer in a minority of subjects. The available data on the kinetics of H. pylori gastritis are limited, but nevertheless very consistent. They suggest that the progression to gland loss or atrophic gastritis among H. pylori-positive subjects occurs at a rate of 1-2% per year. As H. pylori gastritis usually persists for life, a considerable proportion of H. pylori-positive subjects thus eventually show signs of gastric gland loss. The majority of these subjects progress to intestinal metaplasia. Despite these consistent findings in different areas of the world, the incidence of gastric cancer is only moderately related to the prevalence of H. pylori. An example is the so-called African enigma, referring to a low incidence of gastric cancer in certain countries of Africa, despite a high prevalence of H. pylori in all age groups. This is not due to differences in progression to atrophic gastritis; other yet unidentified factors therefore must play a role.

Entities:  

Mesh:

Year:  2000        PMID: 10912474     DOI: 10.1097/00042737-200012060-00003

Source DB:  PubMed          Journal:  Eur J Gastroenterol Hepatol        ISSN: 0954-691X            Impact factor:   2.566


  8 in total

1.  Risk factors for atrophic chronic gastritis in a European population: results of the Eurohepygast study.

Authors: 
Journal:  Gut       Date:  2002-06       Impact factor: 23.059

2.  Novel 180- and 480-base-pair insertions in African and African-American strains of Helicobacter pylori.

Authors:  Shannon L McNulty; Beth M Mole; Daiva Dailidiene; Issy Segal; Reid Ally; Rajesh Mistry; Ousman Secka; Richard A Adegbola; Julian E Thomas; Erik M Lenarcic; Richard M Peek; Douglas E Berg; Mark H Forsyth
Journal:  J Clin Microbiol       Date:  2004-12       Impact factor: 5.948

3.  Helicobacter pylori in gastroduodenal diseases.

Authors:  Oladejo O Lawal; Olorunda Rotimi; Iruka Okeke
Journal:  J Natl Med Assoc       Date:  2007-01       Impact factor: 1.798

Review 4.  Gastroenterology in developing countries: issues and advances.

Authors:  Kate L Mandeville; Justus Krabshuis; Nimzing Gwamzhi Ladep; Chris J J Mulder; Eamonn M M Quigley; Shahid A Khan
Journal:  World J Gastroenterol       Date:  2009-06-21       Impact factor: 5.742

5.  Prevalence of Helicobacter pylori infection, chronic gastritis, and intestinal metaplasia in Mozambican dyspeptic patients.

Authors:  Carla Carrilho; Prassad Modcoicar; Lina Cunha; Mamudo Ismail; Acucena Guisseve; Cesaltina Lorenzoni; Fabiola Fernandes; Bárbara Peleteiro; Raquel Almeida; Céu Figueiredo; Leonor David; Nuno Lunet
Journal:  Virchows Arch       Date:  2008-12-20       Impact factor: 4.064

6.  H. pylori-infection and antibody immune response in a rural Tanzanian population.

Authors:  Sam M Mbulaiteye; Benjamin D Gold; Ruth M Pfeiffer; Glen R Brubaker; John Shao; Robert J Biggar; Michie Hisada
Journal:  Infect Agent Cancer       Date:  2006-09-14       Impact factor: 2.965

Review 7.  Helicobacter Pylori associated global gastric cancer burden.

Authors:  Sam M Mbulaiteye; Michie Hisada; Emad M El-Omar
Journal:  Front Biosci (Landmark Ed)       Date:  2009-01-01

8.  Helicobacter pylori in bottled mineral water: genotyping and antimicrobial resistance properties.

Authors:  Reza Ranjbar; Faham Khamesipour; Nematollah Jonaidi-Jafari; Ebrahim Rahimi
Journal:  BMC Microbiol       Date:  2016-03-12       Impact factor: 3.605

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.